States and education groups have sued the National Institutes of Health over broad funding cuts affecting public health ...
MedPage Today on MSN
COVID continues to take a toll, especially among older adults, study suggests
Koumans and team pointed out that while adults ages 65 and older make up 17.7% of the U.S. population, this group bore a ...
The World Health Organisation (WHO) says its new research shows up-to-date vaccination remains the most effective way to ...
A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several hemophilia advocacy groups confirmed this week. Pfizer is now working with its ...
Pfizer Inc. (NYSE: PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s ...
Pfizer Inc. (NYSE: PFE) on Tuesday gave a first glimpse of its fiscal 2026 guidance. The U.S. pharma giant sees 2026 adjusted earnings of $2.80-$3.00 per share compared to the consensus of $3.06.
Pfizer Inc. provided early 2025 and 2026 guidance, projecting flat-to-declining revenues and EPS, highlighting persistent growth and profitability challenges. Pfizer faces major patent expiries, ...
SHANGHAI, CHINA - 2025/11/08: The Pfizer logo is presented at the 8th China International Import Expo. (Photo by Sheldon Cooper/SOPA Images/LightRocket via Getty Images) Pfizer (PFE) is encountering ...
If I am a Pfizer Inc. (PFE) investor (I used to be, nonetheless), I should have been "elated" at PFE's recent performance against the market, while still getting rewarded with a forward yield that ...
Frankfurt: German agrichemical giant Bayer confirmed to AFP on Wednesday that it was suing American pharmaceutical firms ...
With COVID sales falling and patent protections expiring, Pfizer is forecasting its 2026 revenue to be in the range of $59.5 billion to $62.5 billion. The midpoint of the projection ($61 billion) ...
Dec 23 (Reuters) - A patient who was being treated with Pfizer's (PFE.N), opens new tab hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback